UnitedHealth Group (NYSE:UNH) Upgraded to "Hold" at HSBC

Key Points

• HSBC upgrade: HSBC raised UnitedHealth from "reduce" to "hold" with a $300 price target, implying about a 6.6% upside from the current price.
• Analyst consensus: Most analysts remain positive (one Strong Buy, 18 Buys, 8 Holds, 2 Sells) and MarketBeat shows a "Moderate Buy" consensus with an average target of $364.63, though individual price targets vary widely.
• Catalyst and risks: CMS's finalized 2.48% boost to 2027 Medicare Advantage payments sparked a sharp stock rally and more constructive analyst views, but Q1 results (April 21) and regulatory/execution risks for Optum and cost cuts could reverse sentiment if performance disappoints.

UnitedHealth Group (NYSE:UNH - Get Free Report) was upgraded by equities research analysts at HSBC from a "reduce" rating to a "hold" rating in a research note issued to investors on Tuesday. The brokerage currently has a $300.00 price objective on the healthcare conglomerate's stock. HSBC's target price suggests a potential upside of 6.59% from the company's current price.

A number of other research analysts have also recently commented on UNH. UBS Group cut their price target on shares of UnitedHealth Group from $430.00 to $410.00 and set a "buy" rating on the stock in a report on Wednesday, January 28th. Raymond James Financial upgraded shares of UnitedHealth Group from a "market perform" rating to an "outperform" rating and set a $330.00 price objective for the company in a report on Wednesday, April 1st. Piper Sandler reiterated an "overweight" rating on shares of UnitedHealth Group in a report on Tuesday, January 27th. Barclays lowered their price target on UnitedHealth Group from $391.00 to $327.00 and set an "overweight" rating for the company in a report on Friday, January 30th. Finally, JPMorgan Chase & Co. lowered their price target on UnitedHealth Group from $425.00 to $389.00 and set an "overweight" rating for the company in a report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, UnitedHealth Group currently has an average rating of "Moderate Buy" and a consensus target price of $364.63.

UnitedHealth Group Trading Up 1.5%

UNH opened at $281.46 on Tuesday. The firm has a market cap of $255.48 billion, a P/E ratio of 21.34, a P/E/G ratio of 1.28 and a beta of 0.40. UnitedHealth Group has a 12 month low of $234.60 and a 12 month high of $606.36. The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 0.72. The stock has a 50-day moving average of $281.61 and a 200 day moving average of $319.24.

UnitedHealth Group (NYSE:UNH - Get Free Report) last released its quarterly earnings results on Tuesday, January 27th. The healthcare conglomerate reported $2.11 EPS for the quarter, topping the consensus estimate of $2.09 by $0.02. The company had revenue of $113.73 billion during the quarter, compared to analyst estimates of $113.38 billion. UnitedHealth Group had a return on equity of 14.79% and a net margin of 2.69%.The firm's revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the business posted $6.81 earnings per share. UnitedHealth Group has set its FY 2026 guidance at 17.750- EPS. As a group, research analysts forecast that UnitedHealth Group will post 29.54 EPS for the current year.

Hedge Funds Weigh In On UnitedHealth Group

Large investors have recently bought and sold shares of the business. Sarver Vrooman Wealth Advisors bought a new position in UnitedHealth Group in the fourth quarter worth approximately $25,000. Beacon Financial Strategies CORP acquired a new position in shares of UnitedHealth Group during the fourth quarter worth $26,000. Anfield Capital Management LLC increased its position in shares of UnitedHealth Group by 220.0% during the fourth quarter. Anfield Capital Management LLC now owns 80 shares of the healthcare conglomerate's stock worth $26,000 after purchasing an additional 55 shares in the last quarter. Joseph Group Capital Management acquired a new position in shares of UnitedHealth Group during the fourth quarter worth $27,000. Finally, Nalls Sherbakoff Group LLC acquired a new position in shares of UnitedHealth Group during the fourth quarter worth $27,000. Institutional investors own 87.86% of the company's stock.

Key UnitedHealth Group News

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: CMS finalized a 2.48% increase to 2027 Medicare Advantage payments (roughly $13B+), a much bigger boost than the January proposal and the primary driver of today’s bullish move for insurers including UNH. Trump administration finalizes better-than-feared Medicare Advantage payment rate in boost to health insurers
• Positive Sentiment: Market reaction: UNH spiked in after‑hours/premarket trading (large single‑day gain and notable after‑hours jump), reflecting investor relief that reimbursement pressure is easing. Should you buy UnitedHealth stock after UNH soars 9% in a day
• Positive Sentiment: Analyst sentiment turned constructive: firms (including Raymond James) raised ratings/optimism ahead of Q1, citing better reimbursement visibility and upside to earnings estimates. That supports further upside if results align. Raymond James Boosts UnitedHealth (UNH) Rating Before Q1 Results
• Positive Sentiment: Positive research narrative: bullish writeups argue the CMS move removes a major margin risk and that UNH’s cost‑cuts, AI investments and Optum initiatives can drive margin expansion and above‑consensus earnings by FY2027. UnitedHealth: The CMS Boost Changes Everything Now
• Neutral Sentiment: Upcoming catalyst: UNH reports Q1 results on April 21 — the print will be the immediate test of whether improved reimbursement and cost actions are actually translating into better margins. Is April 21 When UnitedHealth Group Finally Sheds Its Problem Past?
• Negative Sentiment: Near‑term performance and guidance remain risks: UNH has had a difficult recent stretch (material share decline over the past six months), and some recent quarters and guidance were softer than hoped — meaning sentiment can reverse if Q1 misses or cadence disappoints. 2 Reasons to Watch UNH and 1 to Stay Cautious
• Negative Sentiment: Ongoing regulatory/margin uncertainty: other analysts and commentaries stress that regulatory scrutiny and execution on Optum/cost cuts still pose downside if management fails to deliver. UnitedHealth: Why It's Still Not Too Late To Buy The Turnaround

UnitedHealth Group Company Profile

UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

UnitedHealthcare is the company's benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.